These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Shiga toxin triggers endothelial and podocyte injury: the role of complement activation. Zoja C; Buelli S; Morigi M Pediatr Nephrol; 2019 Mar; 34(3):379-388. PubMed ID: 29214442 [TBL] [Abstract][Full Text] [Related]
3. The role of the endothelium in hemolytic uremic syndrome. Zoja C; Morigi M; Remuzzi G J Nephrol; 2001; 14 Suppl 4():S58-62. PubMed ID: 11798147 [TBL] [Abstract][Full Text] [Related]
4. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. Morigi M; Galbusera M; Gastoldi S; Locatelli M; Buelli S; Pezzotta A; Pagani C; Noris M; Gobbi M; Stravalaci M; Rottoli D; Tedesco F; Remuzzi G; Zoja C J Immunol; 2011 Jul; 187(1):172-80. PubMed ID: 21642543 [TBL] [Abstract][Full Text] [Related]
5. Fractalkine and CX3CR1 mediate leukocyte capture by endothelium in response to Shiga toxin. Zanchi C; Zoja C; Morigi M; Valsecchi F; Liu XY; Rottoli D; Locatelli M; Buelli S; Pezzotta A; Mapelli P; Geelen J; Remuzzi G; Hawiger J J Immunol; 2008 Jul; 181(2):1460-9. PubMed ID: 18606701 [TBL] [Abstract][Full Text] [Related]
6. New insights into Shiga toxin-mediated endothelial dysfunction in hemolytic uremic syndrome. Petruzziello-Pellegrini TN; Moslemi-Naeini M; Marsden PA Virulence; 2013 Aug; 4(6):556-63. PubMed ID: 23955166 [TBL] [Abstract][Full Text] [Related]
7. Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome. Buelli S; Zoja C; Remuzzi G; Morigi M Microorganisms; 2019 Jan; 7(1):. PubMed ID: 30634669 [TBL] [Abstract][Full Text] [Related]
8. Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1. Zoja C; Angioletti S; Donadelli R; Zanchi C; Tomasoni S; Binda E; Imberti B; te Loo M; Monnens L; Remuzzi G; Morigi M Kidney Int; 2002 Sep; 62(3):846-56. PubMed ID: 12164866 [TBL] [Abstract][Full Text] [Related]
9. The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice. Petruzziello-Pellegrini TN; Yuen DA; Page AV; Patel S; Soltyk AM; Matouk CC; Wong DK; Turgeon PJ; Fish JE; Ho JJ; Steer BM; Khajoee V; Tigdi J; Lee WL; Motto DG; Advani A; Gilbert RE; Karumanchi SA; Robinson LA; Tarr PI; Liles WC; Brunton JL; Marsden PA J Clin Invest; 2012 Feb; 122(2):759-76. PubMed ID: 22232208 [TBL] [Abstract][Full Text] [Related]
10. Hemolytic uremic syndrome due to Shiga toxin-producing Escherichia coli infection. Bruyand M; Mariani-Kurkdjian P; Gouali M; de Valk H; King LA; Le Hello S; Bonacorsi S; Loirat C Med Mal Infect; 2018 May; 48(3):167-174. PubMed ID: 29054297 [TBL] [Abstract][Full Text] [Related]
11. Platelet thrombus formation in eHUS is prevented by anti-MBL2. Kushak RI; Boyle DC; Rosales IA; Ingelfinger JR; Stahl GL; Ozaki M; Colvin RB; Grabowski EF PLoS One; 2019; 14(12):e0220483. PubMed ID: 31881024 [TBL] [Abstract][Full Text] [Related]
12. Shiga toxins, glycosphingolipid diversity, and endothelial cell injury. Müthing J; Schweppe CH; Karch H; Friedrich AW Thromb Haemost; 2009 Feb; 101(2):252-64. PubMed ID: 19190807 [TBL] [Abstract][Full Text] [Related]
13. Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome. Karpman D; Papadopoulou D; Nilsson K; Sjögren AC; Mikaelsson C; Lethagen S Blood; 2001 May; 97(10):3100-8. PubMed ID: 11342436 [TBL] [Abstract][Full Text] [Related]
14. Shiga toxin 2 and lipopolysaccharide induce human microvascular endothelial cells to release chemokines and factors that stimulate platelet function. Guessous F; Marcinkiewicz M; Polanowska-Grabowska R; Kongkhum S; Heatherly D; Obrig T; Gear AR Infect Immun; 2005 Dec; 73(12):8306-16. PubMed ID: 16299328 [TBL] [Abstract][Full Text] [Related]
15. Shiga toxin-glycosphingolipid interaction: Status quo of research with focus on primary human brain and kidney endothelial cells. Legros N; Pohlentz G; Steil D; Müthing J Int J Med Microbiol; 2018 Dec; 308(8):1073-1084. PubMed ID: 30224239 [TBL] [Abstract][Full Text] [Related]
16. Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS). Exeni RA; Fernandez-Brando RJ; Santiago AP; Fiorentino GA; Exeni AM; Ramos MV; Palermo MS Pediatr Nephrol; 2018 Nov; 33(11):2057-2071. PubMed ID: 29372302 [TBL] [Abstract][Full Text] [Related]
17. Human monocytes stimulated by Shiga toxin 1a via globotriaosylceramide release proinflammatory molecules associated with hemolytic uremic syndrome. Brigotti M; Carnicelli D; Arfilli V; Porcellini E; Galassi E; Valerii MC; Spisni E Int J Med Microbiol; 2018 Oct; 308(7):940-946. PubMed ID: 29983334 [TBL] [Abstract][Full Text] [Related]
18. Shiga toxin-associated hemolytic uremic syndrome: effect of sodium butyrate on sensitivity of human umbilical vein endothelial cells to Shiga toxin. Louise CB; Kaye SA; Boyd B; Lingwood CA; Obrig TG Infect Immun; 1995 Jul; 63(7):2766-9. PubMed ID: 7790096 [TBL] [Abstract][Full Text] [Related]
19. Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers. Nolasco LH; Turner NA; Bernardo A; Tao Z; Cleary TG; Dong JF; Moake JL Blood; 2005 Dec; 106(13):4199-209. PubMed ID: 16131569 [TBL] [Abstract][Full Text] [Related]